Astrazeneca Ab

Rhodia Operations

Rhoda Operations

Rhodia Brasil S.a.

James Woods

Thomas Richard Simpson

James Kang

Yan Li

Cristobal Alhambra

Robert Toms Jacobs

Nemesio Martinez-Castro

Gerard Koether

Ashokkumar Bhikkappa Shenvi

Stefan Berg

Herve Adam

Eifion D Phillips

Derek Pakenham

Jeffrey Albert

James Empfield

Rebecca Urbanek

Sven Hellberg

Cyrus Ohnmacht

Hui-Fang Chang

Timothy Piser

Keith John Herzog

Laurianne Timbart

James Rosamond

Ratan Bhat

Bruce Thomas Dembofsky

Christopher Becker

Kamel Ramdani

Rastko Vukov

Michael Thaddeus Klimas

Jianxing Kang

Jennie McGuire

Howard Prokop

Gerald M Koether

Hui Xiong

Christopher Holmquist

Gerard M Koether

Jeffrey S Albert

Disclosed is a pH responsive polymer made with mono-[2-(methacryloyloxy)ethyl]phthalate and/or mono-[2-(methacryloyloxy)ethyl hexahydro]phthalate. Also disclosed is an aqueous coating composition including at least one latex polymer derived from at least one monomer copolymerized or blended with alkali swellable acrylate copolymer. Also provided is an aqueous coating composition including at least one latex polymer derived from at least one monomer blended with alkali swellable acrylate copolymer, at least one pigment, and water. Also provided is a method of preparing an aqueous coating composition such as a latex paint including the above components. Also provided are methods of preparing mono-[2-(methacryloyloxy)ethyl]phthalate. Also provided are compositions and methods using the polymer in hydraulic fracturing, personal care and or home and industrial cleaners.

Compositions with pH responsive copolymer containing MAEP and/or MAHP and method for using same

Transesterification processes for producing a compound of formula (I)  wherein R1 is H or a methyl group, A and B are each, independently, a linear or branched C2-C5 alkylene group, comprising reacting: an acrylate or methacrylate of formula (II)  wherein R1 is H or a methyl group and R2 is a C1-C4 alkyl group, with a compound of formula (III)  wherein the reaction is performed: (i) in the presence of calcium oxide and calcium hydroxide, and (ii) wherein the molar ratio of the compounds of formula (II) to formula (III) is less than 4:1 or 3:1 respectively.

Process for the preparation of (meth)acrylic esters and derivatives

Compounds of Formula I wherein R, A, R, R, R, R, R, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Alkylsulphonamide quinolines

Compounds of Formula I wherein R, A, R, R, R, R, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Alkyl sulfoxide quinolines as NK-3 receptor ligands

Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, Rand Rare as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.

Nicotinic acetylcholine receptor ligands 101

Compounds of Formula II wherein R, A, R, R, R, R, R, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

This invention relates to novel compounds having formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit secretase and thereby inhibit the production of amyloid &#x3b2; protein, thereby acting to prevent the formation of neurological deposits of amyloid protein. The present invention relates to the treatment of neurological disorders related to amyloid &#x3b2;-protein production such as Alzheimer's disease 

Lactams and uses thereof

Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid &#x3b2; protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit &#x3b3; secretase and thereby inhibit the production of amyloid &#x3b2; protein, thereby acting to prevent the formation of neurological deposits of amyloid protein. 

The present invention relates to new compounds of formula (I) wherein Y, P, R, R, R, n, m are defined as in claim, a process for their preparation and new intermediates used therein, pharmaceutical composition containing said therapeutically active compounds and to the use of said active compounds in therapy, especially in the prevention and/or treatment of dementia related disease, Alzheimer's Disease and conditions associated with glycogen synthase kinase-3 

Compounds for the treatment of dementia related diseases

Growing community of inventors

Wilmington, DE, United States of America

James Woods